STRO SUTRO BIOPHARMA, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%
Returns
ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x
Leverage & solvency
Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $102.48M | $62.04M | $153.73M | $67.77M | $61.88M |
| R&D expense | $166.42M | $252.04M | $180.43M | $137.17M | $104.40M |
| SG&A expense | $41.02M | $48.45M | $62.58M | $59.54M | $56.00M |
| Operating income | -$158.37M | -$238.45M | -$89.28M | -$128.94M | -$98.52M |
| Interest expense | — | — | $1.30M | $2.40M | $2.60M |
| Pretax income | -$191.18M | -$225.10M | -$88.60M | -$116.70M | -$105.54M |
| Income tax | -$93,000 | $2.36M | $18.19M | $2.50M | $0 |
| Net income | -$191.09M | -$227.46M | -$106.79M | -$119.20M | -$105.54M |
| EBITDA | -$151.04M | -$231.24M | -$82.46M | -$123.25M | -$93.68M |
| EPS (basic) | -22.49 | -29.40 | -1.78 | -2.35 | -2.29 |
| EPS (diluted) | -22.49 | -29.40 | -1.78 | -2.35 | -2.29 |
| Weighted avg. shares (diluted) | 8.50M | 7.74M | 60.16M | 50.74M | 46.12M |
| Balance sheet | |||||
| Cash & equivalents | $58.13M | $190.30M | $69.27M | $47.25M | $30.41M |
| Short-term investments | $83.30M | $126.59M | $264.41M | $255.09M | $130.34M |
| Receivables | $3.98M | $8.62M | $36.08M | $7.12M | $12.45M |
| Current assets | $150.93M | $343.31M | $421.54M | $353.15M | $218.51M |
| PP&E, net | $10.65M | $18.19M | $21.94M | $24.62M | $22.55M |
| Total assets | $173.83M | $387.21M | $470.74M | $406.94M | $341.41M |
| Current liabilities | $75.13M | $131.89M | $93.75M | $66.55M | $41.74M |
| Short-term debt | — | — | $4.06M | $12.50M | $9.38M |
| Long-term debt | — | — | $0 | $3.77M | $15.74M |
| Total debt | — | — | $4.06M | $16.27M | $25.11M |
| Total liabilities | $306.28M | $342.61M | $321.09M | $189.90M | $88.84M |
| Shareholders' equity | -$132.45M | $44.60M | $149.65M | $217.05M | $252.56M |
| Net debt | — | — | -$65.21M | -$30.98M | -$5.30M |
| Shares outstanding | 8.58M | 8.31M | 61.01M | 57.50M | 46.33M |
| Cash flow statement | |||||
| Operating cash flow | -$177.23M | -$191.54M | -$111.62M | $3.55M | -$81.68M |
| Investing cash flow | $45.01M | $218.51M | -$3.92M | -$35.02M | -$97.31M |
| Financing cash flow | $44,000 | $94.05M | $137.55M | $48.31M | $3.26M |
| Depreciation & amortization | $7.32M | $7.22M | $6.82M | $5.69M | $4.84M |
| Stock-based compensation | $14.01M | $24.69M | $24.91M | $26.30M | $23.24M |
| Share buybacks | — | — | — | — | $7,000 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.